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MDNCF is a human monocyte-derived, 72-residue chemotactic peptide, which has sequence similarity with members 
of a family of pro-inflammatory cytokines. The peptide was synthesized by the solid-phase method, and is identical to 
the natural pcptide in amino acid composition, sequence and chemotactic potency. MDNCF forms two loops via a neigh- 
boring pair of disulfide bridges, the probable locations of which are residues 7-34 and 950. Reduction and alkylation 
eliminated chemotactic activity. MDNCF fragments 7-37, 3&72 and 17-72 were all biologically inactive. The data sug- 
gest that the region of the clustered pair of disulfide bridges is important for biological activity. 
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1. INTRODUCTION 
We recently described [1,2] the isolation and 
purification to homogeneity of a human monocyte- 
derived, neutrophil chemotactic factor (MDNCF). 
Reports on the isolation of the molecule appeared 
from two other laboratories at about the same time 
[3,4]. MDNCF was purified from culture fluid of 
LPS-stimulated human mononuclear cells in a 
series of steps that included ion-exchange 
chromatography, gel filtration and reverse-phase 
HPLC. Amino acid analysis and sequence data 
show that MDNCF is a unique molecule that dif- 
fers completely from known cytokines [2]. The 
cDNA for MDNCF was recently cloned [5], and is 
identical, to a cDNA derived from the mRNA of 
staphylococcal enterotoxin-stimulated human 
blood mononuclear cells [6]. The cDNA contains a 
coding sequence of 99 residues, the last 72 of which 
correspond to MDNCF. We undertook the solid- 
phase synthesis of MDNCF as well as portions of 
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the molecule, in order to investigate structure- 
activity relationships. 
2. MATERIALS AND METHODS 
2.1. Synthesis of MDNCF and portions of MDNCF 
MDNCF was synthesized with a solid-phase synthesizer 
(model 43OA, Applied Biosystems, Foster City, CA). Boc- 
Ser(Bzl)-PAM resin (0.28 mmol/g) or Boc-Thr(Bzl)-PAM resin 
(0.696 mmol/g) was placed in the reaction vessel. Boc-amino 
acid derivatives were coupled in DMF by the symmetric an- 
hydride method, except for Boc-Asn, Boc-Arg(Tos), and Boc- 
Gin, which were coupled by the HOBT ester method. The 
following side chain protection groups were used: 
Asp(OcHEX), Glu(OcHEX), Ser(Bzl), Thr(Bzl), Lys(CI-z), 
Arg(Tos), His(Z), Trp(CHO), and Tyr(Br-Z). Arg, Asn, Gln, 
His, Ile and Val were coupled twice. After coupling, remaining 
amino groups were capped by acetic anhydride. The low-high 
HF procedure was used for deprotection and cleavage from 
resin. 600 mg of resin was equilibrated first with 10 ml of 
dimethyl : : 5 : 22.5) at 
- 3°C for 2 h, and then with 10 ml ofp-cresol/p-thiocresol/HF 
(7.5 : 5 : 87.5) for 1 h. After the resin was washed with ether con- 
taining 1% mercaptoethanol, the peptide was extracted with 5% 
acetic acid containing 20 mM mercaptoethanol. 
2.2. 
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Sephadex G-25 or G-50 equilibrated with 5% acetic acid con- 
taining 20 mM 2-mercaptoethanol. Peptides were further 
purified on a Vydac C-4 HPLC column with a gradient from a 
starting composition of 0.05% TFA in water to a limit of 0.05% 
TFA in acetonitrile. After reduction of peptides in DTT, air ox- 
idation was induced by dialysis for 2 days at 4°C against 0.05 M 
Tris-HCI buffer, pH 9.0, containing 1 M urea. Amino acid 
composition was determined with a Waters Picotag system 
(Waters Corp., Milford, MA) on samples hydrolyzed 24 h in the 
gas phase above 6 M HCI in vacua at 110°C. N-terminal se- 
quence was determined by Edman degradation on an automated 
Applied Biosystems 470A sequencer. For studies on reduced 
MDNCF, samples were treated with 10 mM DTT in 7 M 
guanidine, 0.3 M Tris, pH 8.5, alkylated with 22 mM iodo- 
acetic acid or iodoacetamide, and dialyzed against 50 mM Tris, 
pH 8.3. 
2.3. Chemotaxis assay 
The chemotactic activity of peptides for human neutrophils 
was measured in multiwell chemotaxis chambers [7]. In this 
assay, cells migrate from upper wells through 3 pm diameter 
holes in a polycarbonate membrane toward attractant in lower 
wells. Since the migrated cells adhere to the under side of the 
membrane, they can be stained and counted for quantification 
of their response. 
3. RESULTS AND DISCUSSION 
3.1. Synthesis of MDNCF (l-72) and partial 
sequences of MDNCF 
MDNCF (l-72) and partial sequences (17-72, 
30-72 and 7[Ala substituted for Cys]-37) were syn- 
thesized as described. Amino acid composition of 
oxidized and purified peptides was in good agree- 
ment with predicted values. The oxidized form of 
synthetic MDNCF was eluted at the same position 
as native MDNCF on reverse-phase HPLC. A 
single, high yield N-terminal sequence of synthetic 
MDNCF (l-72) was obtained, which was in ex- 
cellent agreement with native MDNCF (table 1). 
3.2. Chemotactic activity of synthetic MDNCF 
Potency and efficacy of native and synthetic 
MDNCF as chemoattractants for human 
neutrophils were compared. Fig.1 shows that the 
concentration required for a maximal response 
(potency) and the percentage of neutrophils 
migrating at the optimal concentration (efficacy) 
were virtually identical for the two peptides. The 
decline in response at concentrations above the op- 
timal is typical for pure chemoattractants. 
3.3. Structure-activity correlations 
MDNCF has 4 cysteines, located in positions 7, 
468 
9, 34 and 50. In purified native MDNCF these cys- 
teines are apparently oxidized, since addition of 
radioactive iodoacetic acid without reduction 
resulted in no detectable incorporation. In the case 
of ,0-thromboglobulin, a peptide with sequence 
similarity to MDNCF [2] and which has 4 cysteines 
in the same locations as MDNCF, the peptide is in 
the form of 2 loops, created by disulfide bridges at 
residues 7-34 and 9-50 [8]. It is likely, therefore, 
that the MDNCF configuration is similar. To 
determine if the oxidized form is required for 
biological activity, we added dithiothreitol to a 
solution of native MDNCF, which was unfolded in 
7 M guanidine hydrochloride; an aliquot of the 
reduced peptide was then alkylated with iodoacet- 
amide. Chemotactic activity of native MDNCF was 
compared with the reduced or the reduced and 
alkylated preparations. Fig.2 shows that the poten- 
cy and the efficacy of reduced MDNCF were com- 
parable to the untreated (oxidized) peptide, prob- 
ably because of re-oxidation; whereas the reduced 
and alkylated preparation was practically devoid of 
activity. 
Two different peptide fragments were synthe- 
sized and oxidized to form loops via disulfide 
bridging. One fragment comprised residues 7-37, 
in which the position 7 cysteine was replaced by 
alanine, so that the oxidized peptide had a disulfide 
bond between residues 9 and 34. This forms a loop 
comparable to the loop created by a disulfide bond 
between residues 7 and 34 of the native molecule 
(fig.3, loop 1). The other was fragment 30-72, with 
a disulfide bond between residues 34 and 50. Since 
the proximity of cysteines 7 and 9 in the native pep- 
tide brings the 2 disulfide bridges close together, 
the 34-50 disulfide bond creates a loop containing 
almost the same residues as the native 9-50 loop 
(fig.3, loop 2). These two peptide fragments were 
completely devoid of chemotactic activity. Frag- 
ment 17-72, which cannot assume the 2-100~ con- 
figuration since it is devoid of cysteines 7 and 9, 
also had no chemotactic activity. In another test 
for ligand-neutrophil interaction, peptide frag- 
ments added to neutrophil suspensions in the cell 
wells of the chemotactic chamber did not prevent 
migration toward native MDNCF in the attractant 
wells. In contrast, 10-7 M native MDNCF in the 
neutrophil suspension inhibited the chemotactic 
response to 10-8 M MDNCF in the attractant 
wells. 
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Table 1 
August 1988 
Sequence analysis of synthetic MDNCF (320 pmol) 
Cycle 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
a Not detected 
Residue 
S 
A 
K 
E 
L 
R 
: 
C 
I 
K 
I 
Y 
S 
K 
P 
F 
H 
P 
K 
Yield (pmol) 
234 
167 
149 
162 
132 
95 
ND” 
110 
ND 
87 
85 
46 
56 
32 
27 
41 
37 
10 
25 
13 
Cycle Residue Yield (pmol) 
21 F 16 
22 1 16 
23 K 9 
24 E 7 
25 L 16 
26 R 11 
27 V 9 
28 I 11 
29 E 7 
30 S 6 
31 G 5 
32 P 6 
33 H ND 
34 C ND 
35 A 3 
36 N 0.8 
37 T 0.5 
38 E 1.3 
39 I 1.3 
The deduced complete sequence of MDNCF [5] is as follows: 
10 20 30 40 50 60 70 
SAKELRCQCIKTYSKPFHPKFIKELRVIESGPHCANTEIIVKLSDGRELCLDPKENWVQRVVEKFLKRAENS 
I I I I I I I 
<lo-‘0 10-9 4x10-9 10-a 3x10-8 10-7 3x10-7 
Concentration (M) 
Fig. 1. Neutrophil chemotactic response to native and synthetic Fig.2. Effect of reduction and alkylation on MDNCF chemo- 
MDNCF. tactic activity. 
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Fig.3. Loop configuration, based on disulfide locations of ,& 
thromboglobulin. 
Studies of the oxidized peptide fragments lead to 
the following conclusions and speculations. 
Neither the carboxyl-terminus nor either of the 
synthetic loops formed by disulfides 7-34 or 34-50 
are sufficient for biological activity. It is unlikely 
that the amino-terminus is the active site, since ac- 
tivity is unaltered by extensions of the amino- 
terminus (Yoshimura et al., submitted). Of added 
interest is the fact that neither of the loops inhibits 
activity of intact MDNCF. This indicates that they 
cannot inhibit the interaction of MDNCF with 
neutrophil-saturable MDNCF binding sites, which 
have recently been demonstrated (Leonard et al., 
unpublished). When these observations are con- 
sidered in the light of the inactivity of reduced and 
alkylated MDNCF, it appears likely that the region 
of the clustered pair of disulfide bridges is impor- 
tant for biological activity. 
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